GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » YoY EPS Growth

Cidara Therapeutics (FRA:20D0) YoY EPS Growth : 26.84% (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Cidara Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2025 was 26.84%.

Cidara Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was €-1.54.

Cidara Therapeutics YoY EPS Growth Historical Data

The historical data trend for Cidara Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics YoY EPS Growth Chart

Cidara Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.00 51.55 36.79 46.88 -430.66

Cidara Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -474.64 -566.34 -16.59 -710.11 26.84

Cidara Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Cidara Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(-25.546--4.814)/ | -4.814 |
=-430.66 %

Cidara Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EPS Growth (Q: Mar. 2025 )
=(Earnings per Share (Diluted) (Q: Mar. 2025 )-Earnings per Share (Diluted) (Q: Mar. 2024 )) / | Earnings per Share (Diluted) (Q: Mar. 2024 )) |
=(-1.535--2.098)/ | -2.098 |
=26.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cidara Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cidara Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » YoY EPS Growth
Comparable Companies
CADL ALMS THRD FHTX NVCT AVIR CRVS VNDA HUMA PLX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CDTX:USA
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Website
https://www.cidara.com
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Headlines

No Headlines